KHALID ARSHAD: Open Payments
NPI 1306259817 · KANKAKEE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,610 in 78 payments from 15 companies in 2025. Trend: 2023 $1,775 · 2024 $1,996 · 2025 $1,610
Food & beverage: $1,610
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $427 |
| Neurocrine BioSciences, Inc. | 14 | $306 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $151 |
| Alkermes, Inc. | 7 | $133 |
| Supernus Pharmaceuticals, Inc. | 6 | $126 |
| Tris Pharma Inc | 6 | $112 |
| Axsome Therapeutics, Inc. | 4 | $105 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| Luye Pharma (USA) Ltd. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
Products named: INGREZZA, REXULTI, ABILIFY ASIMTUFII, CAPLYTA, ARISTADA, Qelbree, Dyanavel XR, Auvelity.
Industry payments across IL — which companies pay providers there.
